These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27192619)

  • 1. QuilliChew ER--extended-release chewable methylphenidate tablets.
    Med Lett Drugs Ther; 2016 May; 58(1495):68-9. PubMed ID: 27192619
    [No Abstract]   [Full Text] [Related]  

  • 2. QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above.
    Childress A; Ponce De Leon B; Owens M
    Expert Opin Drug Deliv; 2018 Dec; 15(12):1263-1270. PubMed ID: 30404549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
    Cortese S; D'Acunto G; Konofal E; Masi G; Vitiello B
    CNS Drugs; 2017 Feb; 31(2):149-160. PubMed ID: 28130762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotempla XR-ODT--another long-acting methylphenidate for ADHD.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):183-185. PubMed ID: 29125594
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder.
    Cox DJ; Mikami AY; Cox BS; Coleman MT; Mahmood A; Sood A; Moore M; Burket R; Merkel RL
    Arch Pediatr Adolesc Med; 2008 Aug; 162(8):793-4. PubMed ID: 18678816
    [No Abstract]   [Full Text] [Related]  

  • 6. Quillivant XR--an extended release oral suspension of methylphenidate.
    Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
    [No Abstract]   [Full Text] [Related]  

  • 7. Aptensio XR--another long-acting methylphenidate.
    Med Lett Drugs Ther; 2015 Jul; 57(1473):101-3. PubMed ID: 26204039
    [No Abstract]   [Full Text] [Related]  

  • 8. Methylphenidate transdermal system.
    Mays DA; Findling R
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223. PubMed ID: 16292112
    [No Abstract]   [Full Text] [Related]  

  • 9. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole.
    Abbas R; Childress AC; Nagraj P; Rolke R; Berry SA; Palumbo DR
    Clin Ther; 2018 May; 40(5):733-740. PubMed ID: 29703430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OROS methylphenidate-induced skin eruptions.
    Coskun M; Tutkunkardas MD; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):593-4. PubMed ID: 19877987
    [No Abstract]   [Full Text] [Related]  

  • 12. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of switching to once-daily modified-release methylphenidate from previous treatment with other psychostimulants in children and adolescents with ADHD: an observational study with clinician, parent, and teacher evaluations.
    Frölich J; Breuer D; Görtz-Dorten A; Amonn F; Fischer R; Döpfner M
    J Clin Psychopharmacol; 2014 Feb; 34(1):168-71. PubMed ID: 24346749
    [No Abstract]   [Full Text] [Related]  

  • 14. Focalin XR for ADHD.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
    Olders H
    J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
    [No Abstract]   [Full Text] [Related]  

  • 17. Jornay PM -- evening-dosed methylphenidate for ADHD.
    Med Lett Drugs Ther; 2019 Aug; 61(1578):126-128. PubMed ID: 31386648
    [No Abstract]   [Full Text] [Related]  

  • 18. Two new amphetamines for ADHD.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):80-1. PubMed ID: 27305069
    [No Abstract]   [Full Text] [Related]  

  • 19. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
    World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.